Scholar Rock Holding (SRRK) Equity Average (2018 - 2026)
Scholar Rock Holding's quarterly Equity Average came in at $260.8 million in Q1 2026, down 23.42% year-on-year from $340.5 million in Q1 2025, and up 6.32% quarter-over-quarter from $245.2 million in Q4 2025.
Scholar Rock Holding has reported Equity Average for 9 years, with the latest figure at $260.8 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 23.42% year-over-year to $260.8 million; the trailing twelve-month figure through Mar 2026 stood at $260.8 million (down 23.42% YoY), and the FY2025 full-year result was $307.1 million, up 3.41% from the prior year.
- Equity Average for Q1 2026 stood at $260.8 million, up from $245.2 million in the prior quarter.
- The five-year high for Equity Average was $340.5 million in Q1 2025, with the low at $106.4 million in Q3 2024.
- Average Equity Average over 5 years is $229.6 million, with a median of $239.1 million recorded in 2025.
- Year-over-year, Equity Average tumbled 42.51% in 2024 and jumped 124.74% in 2025.
- Tracing SRRK's Equity Average over 5 years: stood at $276.8 million in 2022, then dropped by 29.02% to $196.4 million in 2023, then climbed by 13.99% to $223.9 million in 2024, then rose by 9.52% to $245.2 million in 2025, then advanced by 6.32% to $260.8 million in 2026.
- The last three Equity Average figures came in at $260.8 million (Q1 2026), $245.2 million (Q4 2025), and $239.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 260.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 260.75 Mn |
| Dec 31, 2025 | 245.24 Mn |
| Sep 30, 2025 | 239.14 Mn |
| Jun 30, 2025 | 272.81 Mn |
| Mar 31, 2025 | 340.48 Mn |
| Dec 31, 2024 | 223.92 Mn |
| Sep 30, 2024 | 106.41 Mn |
| Jun 30, 2024 | 158.20 Mn |
| Mar 31, 2024 | 204.00 Mn |
| Dec 31, 2023 | 196.44 Mn |
| Sep 30, 2023 | 185.08 Mn |
| Jun 30, 2023 | 215.58 Mn |
| Mar 31, 2023 | 244.44 Mn |
| Dec 31, 2022 | 276.75 Mn |
| Sep 30, 2022 | 311.39 Mn |
| Jun 30, 2022 | 250.41 Mn |
| Mar 31, 2022 | 171.70 Mn |
| Dec 31, 2021 | 179.67 Mn |
| Sep 30, 2021 | 201.96 Mn |
| Jun 30, 2021 | 228.60 Mn |
| Mar 31, 2021 | 250.66 Mn |
| Dec 31, 2020 | 161.87 Mn |
| Sep 30, 2020 | 72.58 Mn |
| Jun 30, 2020 | 90.41 Mn |
| Mar 31, 2020 | 105.77 Mn |
| Dec 31, 2019 | 117.35 Mn |
| Sep 30, 2019 | 125.37 Mn |
| Jun 30, 2019 | 113.24 Mn |
| Mar 31, 2019 | 102.07 Mn |
| Dec 31, 2018 | 104.48 Mn |
| Sep 30, 2018 | 106.98 Mn |
| Jun 30, 2018 | 24.84 Mn |
| Mar 31, 2018 | -57.73 Mn |